Search the PBPK Model Repository

Quickly find freely available drug and population models in our PBPK model repository.

The models provided have been collated from published examples which authors have shared in our Published Model Collection or developed as part of various global health projects in our Global Health Collection. This search facility searches both model collections simultaneously.

To contribute published user compound and/or population files, upload your files here: Upload Model Files

Searching Tips

You can use a * character as a wildcard at the end of a alphanumeric search term. The search term must start with at least one character before the wildcard. E.g., Rifam* will get you “Rifampicin” and “Rifampin”.
You can also use a * character as a wildcard in the middle of a alphanumeric search term. The search term must still start with at least one character before the wildcard. E.g., Rif*in will also get you “Rifampicin” and “Rifampin” .
You can also use a * character as a wildcard at the start of a alphanumeric search term. However you must use forward slashes to delimit the search term and use a point before the wildcard. E.g., /.*picin/ will only get you “Rifampicin”.

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Found 126 Matches

Amodiaquine

Model Files Publication

Brand Name(s) include: Basoquin, Camoquin, Flavoquin, Coarsucam

Disease: Malaria

Drug Class: Antimalarials

Date Updated: June 2021

The model at-a-glance

Absorption Model	First-Order
Volume of Distribution	Full PBPK (Method 2)
Route of Elimination	CYP2C8 = 72%; Additional HLM = 28%
Perpetrator DDI	CYP2D6
Validation	Four clinical studies describing single and multiple dose exposure of amodiaquine were used to verify the PBPK model. In comparison of predicted vs. observed AUC, 75% of the studies were 2-fold and 50% were within 1.5-fold. A clinical DDI study where amodiaquine was the victim of a CYP2C8-mediated DDI was accurately recovered using the PBPK model.
Limitations	Clinical data has not been used to verify amodiaquine as a perpetrator of CYP2D6-mediated DDIs
Updates in V19	Updated in vitrodata fu: 0.033 -> 0.089 B:P: 1.3 -> 1.1 DEAQ Ki for CYP2D6 (µM) – 1.7 -> 1.6 Converted from minimal PBPK model to full PBPK model Recalculated retrograde clearance for CYP2C8 CL_int and additional HLM CL_int

Search Score: 2

V19 Res Boosted Atazanavir April 2021

Model Files Publication

V19 Res Boosted Atazanavir April 2021

Search Score: 2

Avibactam_V15R1_USFDA_20170810

Model Files Publication

http://onlinelibrary.wiley.com/doi/10.1002/cpt.750/full Avibactam compound file in healthy volunteers. Evaluation of the effect of renal impairment on PK of OAT substrates

Search Score: 2

Chloroquine_V18R2_PekingUniversityThirdHospital_20200317

Model Files Publication

A perfusion limited full PBPK model of chloroquine published in Clin Inf Dis in 2020, the model includes an additional organ that can be used to represent lung tissue accumulation of the drug. Please note a custom dosing for 66 days has been included in the file.

Search Score: 1

Search the PBPK Model Repository

Searching Tips

Amodiaquine

The model at-a-glance

V19 Res Boosted Atazanavir April 2021

Avibactam_V15R1_USFDA_20170810

Chloroquine_V18R2_PekingUniversityThirdHospital_20200317

Your Privacy